Literature DB >> 25798811

Clinical, Histologic, and Molecular Analysis of Differences Between Erythematotelangiectatic Rosacea and Telangiectatic Photoaging.

Yolanda R Helfrich1, Lisa E Maier1, Yilei Cui1, Gary J Fisher1, Heather Chubb1, Suzanne Fligiel2, Dana Sachs1, James Varani3, John Voorhees1.   

Abstract

IMPORTANCE: Facial erythema and telangiectasia are commonly associated with the erythematotelangiectatic subtype of rosacea (ETR). It is important for clinicians to recognize that these findings can also be associated with a subtype of photoaging, which we term telangiectatic photoaging (TP).
OBJECTIVE: To demonstrate that ETR and TP are distinct dermatologic disorders.
DESIGN: A case-control observational study comparing clinical, histologic, and gene expression features of 26 participants with ETR, 20 with TP, and 11 age- and sex-matched controls in the Program for Clinical Research in Dermatology at University of Michigan. MAIN OUTCOMES AND MEASURES: Findings of clinical history and examination, light and electron microscopy, immunohistochemical analyses, and real-time quantitative reverse-transcriptase polymerase chain reaction gene expression.
RESULTS: Transient erythema was greater in the ETR group (38% graded moderate to severe) than in the TP (0%; P < .001) and control groups (0%; P = .002). Nontransient erythema was also greater in the ETR group (50% graded moderate to severe) than in the TP (25%; P = .03) and control groups (0%; P < .001). Participants with ETR tended to have erythema and telangiectasia primarily on the central face (79%), whereas those with TP tended to have more lateral involvement (57%; P < .001). Those with ETR had significantly less clinical evidence of photodamage (0% graded 6-8 on a photonumeric scale) than those with TP (40% graded 6-8; P = .01). Histologically, there was less evidence of photodamage in ETR than in TP, which had wispy collagen and solar elastosis surrounding blood vessels. Immunohistologic analysis demonstrated greater geometric mean immunostained area by mast cell tryptase staining in ETR samples (0.018%) than in TP (0.004%; P = .01) or control samples (0.001%; P < .001) but no increase in mast cell number, indicative of greater mast cell degranulation. Gene expression of matrix metalloproteinase-3 was 4-fold greater in ETR samples than in TP samples (P = .004) and 5-fold higher than in control samples (P = .004). Gene expression of the neuropeptides calcitonin gene-related peptide (CGRP-α) and substance P was significantly increased in ETR compared with TP (9-fold [P < .001] and 5-fold [P = .002], respectively) and control samples (10-fold [P < .001] and 28-fold [P < .001], respectively). CONCLUSIONS AND RELEVANCE: Telangiectatic photoaging is characterized by less transient and nontransient erythema, a more lateral distribution of erythema and telangiectasia, less neurogenic mast cell activation, and less MMP-mediated matrix remodeling than ETR. These data demonstrate that TP is a distinct clinical entity from ETR that can be distinguished on the basis of clinical, histologic, and gene expression findings.

Entities:  

Mesh:

Year:  2015        PMID: 25798811     DOI: 10.1001/jamadermatol.2014.4728

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  13 in total

1.  Long-pulsed 1064-nm Nd: YAG laser ameliorates LL-37-induced rosacea-like skin lesions through promoting collagen remodeling in BALB/c mice.

Authors:  Miri Kim; Jongsic Kim; Seo-Won Jeong; Hyunmu Jo; Hyun Jeong Park
Journal:  Lasers Med Sci       Date:  2017-12-18       Impact factor: 3.161

Review 2.  Rosacea and Diet: What is New in 2021?

Authors:  Tamara Searle; Faisal R Ali; Sarah Carolides; Firas Al-Niaimi
Journal:  J Clin Aesthet Dermatol       Date:  2021-12

Review 3.  Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features.

Authors:  Giuseppe Micali; Peter Arne Gerber; Francesco Lacarrubba; Gregor Schäfer
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

4.  Clinical Skin Aging Score and Risk of Degenerative Cardiovascular Diseases.

Authors:  Soheir Ghonemy; Mohamed Mohamed Mahmoud Nasr; Mohammad Soliman; Heba Allah Hosiney
Journal:  J Clin Aesthet Dermatol       Date:  2021-02-01

5.  Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component.

Authors:  Giuseppe Micali; Federica Dall'Oglio; Anna Elisa Verzì; Ivano Luppino; Karishma Bhatt; Francesco Lacarrubba
Journal:  Lasers Med Sci       Date:  2017-09-09       Impact factor: 3.161

Review 6.  Skin neurogenic inflammation.

Authors:  Jae Eun Choi; Anna Di Nardo
Journal:  Semin Immunopathol       Date:  2018-04-30       Impact factor: 9.623

Review 7.  Multifaceted MRGPRX2: New insight into the role of mast cells in health and disease.

Authors:  Saptarshi Roy; Chalatip Chompunud Na Ayudhya; Monica Thapaliya; Vishwa Deepak; Hydar Ali
Journal:  J Allergy Clin Immunol       Date:  2021-05-04       Impact factor: 14.290

Review 8.  Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.

Authors:  Martin Steinhoff; Marc Vocanson; Johannes J Voegel; Feriel Hacini-Rachinel; Gregor Schäfer
Journal:  Adv Ther       Date:  2016-07-18       Impact factor: 3.845

Review 9.  Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy.

Authors:  James R Docherty; Martin Steinhoff; Dianne Lorton; Michael Detmar; Gregor Schäfer; Anna Holmes; Anna Di Nardo
Journal:  Adv Ther       Date:  2016-08-25       Impact factor: 3.845

Review 10.  Rosacea: Epidemiology, pathogenesis, and treatment.

Authors:  Barbara M Rainer; Sewon Kang; Anna L Chien
Journal:  Dermatoendocrinol       Date:  2017-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.